Regarding my prior post about VanKasper report of 11-19-96 - I now have it in front of me - my memory was a little faulty but the report is still good with fy97 + fy98 eps estimates of $.12 + $.20, respectively - also , re 25-30% eps growth per year, the report actually says "Quidel anticipates that the physician-office and home-use market segment, in particular, will develop and grow substantially over the next three to five years. We estimate this growth to be in the range of 25-30% per year" Sorry for the errors - my memory ain't what it used to be - the report also says QDEL is an "emerging leader" in poc rapid diagnostic industry, cites "favorable health care trends" and "favorable consumer trends", "new distribution partners" (Ansell, w/ its "major promotional campaign beginning in July, 1996. Targeted in this campaign are increased sales through major chain stores such as KMart, WalMart, Walgreen's and Revco"), strong product line", esp chlamydia, H. pylori and strep a test, "scientific validation" as shown by collaboration w/ Glaxo and Bayer, and "earnings acceleration", noting:
"The shares of Quidel have been weak recently, even after the developments mentioned above. We see this weakness as a buying opportunity. Our forecast call for earnings growth of 300% to $0.12 per share for FY97 and 67% to $0.20 for FY98. We reiterate our Long-Term Buy on the shares of Quidel with a 12-month price of $6 per share and recommend purchase for the long-term investor."
I couldn't say it better myself!
BOB |
